Mylan is engaged in the global development, licensing, manufacture, marketing and distribution of generic, branded generic, brand-name and over-the-counter (OTC) pharmaceutical products for resale by others and active pharmaceutical ingredients (API) through three reportable segments on a geographic basis, North America, Europe and Rest of World. Co.'s API business is conducted through its subsidiary, Mylan Laboratories Limited, which is included within its Rest of World segment. Among Co.'s branded prescription products are EpiPen® Auto-Injector, Perforomist® Inhalation Solution and Dymista®. Co.'s OTC portfolio includes Cold-EEZE®, MidNite® and Vivarin®, as well as other products. The MYL stock yearly return is shown above.
The yearly return on the MYL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MYL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|